Investigation of the Bioaccessibility of Progesterone (Micronized and Nonmicronized), Using an In Vitro Model of the Human Gastrointestinal System
Michelle R.A. de Almeida, August S. Bassani, Samia Hamid, Daniel Banov, Ha Phan
Abstract
The aim of this study is to evaluate the bioaccessibility of two progesterone oral formulations (micronized
progesterone 100 mg SR capsules and milled progesterone 100 mg SR capsules), using an in vitro model of the
human GI tract. Results show that overall bioaccessibility of micronized progesterone (21.8%) was significantly
greater than that of milled progesterone (1.9%), p < 0.001. The higher total bioaccessibility could potentially be
due to the smaller particle size of micronized progesterone (< 6 μm), in comparison to that of milled
progesterone (approximately 92 μm). One may hypothesize that oral compounded micronized progesterone has
the potential for greater bioavailability because of the significantly higher bioaccessibility of micronized
progesterone in comparison to milled progesterone. Knowledge of this study’s results may be useful for
practitioners when justifying the viability of using micronized progesterone over milled progesterone in the
management of postmenopausal symptoms.
Full Text: PDF